RSV-related hospitalization and outpatient palivizumab use in very preterm (born at

Autor:	Elizabeth R. Packnett, Isabelle H. Winer, Heather Larkin, Abiola Oladapo, Tara Gonzales, Matthew Wojdyla, Mitchell Goldstein, Vincent C. Smith
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	respiratory syncytial virus respiratory tract infections infant premature pre-exposure prophylaxis pediatric hospitalization Immunologic diseases. Allergy RC581-607 Therapeutics. Pharmacology RM1-950
Zdroj:	Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
Druh dokumentu:	article
ISSN:	2164-5515 2164-554X 21645515
DOI:	10.1080/21645515.2022.2140533
Popis:	Respiratory syncytial virus (RSV) is a leading cause of bronchiolitis and pneumonia in children under one year and a leading cause of infant hospitalization. Palivizumab was approved by the FDA in 1998 as RSV immunoprophylaxis to prevent severe RSV disease in children with specific health conditions and those born at 37 wGA) infants. Using the MarketScan Commercial and Multi-State Medicaid administrative claims databases, infants born between 7/1/2003 and 6/30/2020 were identified and classified as very preterm or term. Infants with evidence of health conditions, such as congenital heart disease and cystic fibrosis, were excluded. During 2003–2020 RSV seasons (November to March), claims incurred by infants while they were
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/6b66e6d3a8c14c57a799f9529b689f38 Zobrazit plný text záznamu View record in DOAJ